A Randomized, Double-blind, Double-dummy, Placebo- and Positive-controlled Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs AL 335 (Primary) ; Moxifloxacin; Odalasvir; Simeprevir
- Indications Hepatitis C
- Focus Pharmacodynamics
- Sponsors Janssen Research & Development
- 11 Oct 2017 Planned End Date changed from 23 Nov 2017 to 19 Oct 2017.
- 11 Oct 2017 Planned primary completion date changed from 23 Nov 2017 to 19 Oct 2017.
- 11 Aug 2017 Planned number of patients changed from 105 to 140.